Prevalence of the activating JAK2 tyrosine kinase mutation V617F in the Budd-Chiari syndrome.

No abstract is available for this paper.

• Publication year

  2005

• Venue

  Gastroenterology

• Publication date

  2005-11-16

• Fields of study

  Medicine

• Identifiers
  DOI 10.1053/J.GASTRO.2006.04.008PMID 16762626
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Interpretation of measured red cell mass and plasma volume in males with elevated venous PCV values.

  2009cited by this paper
• Risk factors for thrombophilia in extrahepatic portal vein obstruction

  2005cited by this paper
• On the molecular origins of the chronic myeloproliferative disorders: it all makes sense.

  2005cited by this paper
• JAK2V617F mutation in essential thrombocythaemia: clinical associations and long‐term prognostic relevance

  2005cited by this paper
• A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera

  2005cited by this paper
• Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis.

  2005cited by this paper
• A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera.

  2005cited by this paper
• On the molecular origins of the chronic myeloproliferative disorders: it all makes sense.

  2005cited by this paper
• A gain-of-function mutation of JAK2 in myeloproliferative disorders.

  2005cited by this paper
• Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders.

  2005cited by this paper
• Thrombopoietin enhances expression of vascular endothelial growth factor (VEGF) in primitive hematopoietic cells through induction of HIF-1alpha.

  2004cited by this paper
• The World Health Organization (WHO) classification of the myeloid neoplasms.

  2002cited by this paper
• Liver transplantation for Budd-Chiari syndrome.

  2002cited by this paper
• Hematologic aspects of liver transplantation for Budd-Chiari syndrome with special reference to myeloproliferative disorders1

  2002cited by this paper
• Portal or hepatic vein thrombosis as the first presentation of a myeloproliferative disorder in patients with normal peripheral blood counts.

  2002cited by this paper
• Polycythemia vera: analysis of DNA from blood granulocytes using comparative genomic hybridization.

  2001cited by this paper
• Evaluation of diagnostic criteria in polycythemia vera.

  2001cited by this paper
• Cause of portal or hepatic venous thrombosis in adults: The role of multiple concurrent factors

  2000cited by this paper
• Outcome of Budd‐Chiari syndrome: A multivariate analysis of factors related to survival including surgical portosystemic shunting

  1999cited by this paper
• Therapeutic Dilemmas: Balancing the Risks of Bleeding, Thrombosis, and Leukemic Transformation in Myeloproliferative Disorders (MPD)

  1997cited by this paper
• Spontaneous Erythroid Colony Formation as the Clue to an Underlying Myeloproliferative Disorder in Patients with Budd-Chiari Syndrome or Portal Vein Thrombosis

  1997cited by this paper
• Diagnostic applications of haemopoietic progenitor culture techniques in polycythaemias and thrombocythaemias.

  1996cited by this paper
• Identification of latent myeloproliferative disease in patients with Budd‐Chiari syndrome using X‐chromosome inactivation patterns and in vitro erythroid colony formation

  1995cited by this paper
• Liver transplantation for Budd-Chiari syndrome.

  1994cited by this paper
• The changing scene of hepatic vein thrombosis: recognition of asymptomatic cases.

  1994cited by this paper
• Portal hypertension as presenting feature of a myeloproliferative disorder. Diagnosis and therapeutic dilemmas.

  1993cited by this paper
• Portasystemic shunting versus liver transplantation for the Budd-Chiari syndrome.

  1991cited by this paper
• Primary polycythaemia: positive diagnosis using the differential response of primitive and mature erythroid progenitors to erythropoietin, interleukin 3 and alpha‐interferon

  1990cited by this paper
• Incidence and risk factors for thrombotic complications in a historical cohort of 100 patients with essential thrombocythemia.

  1990cited by this paper
• In vitro colony culture and chromosomal studies in hepatic and portal vein thrombosis--possible evidence of an occult myeloproliferative state.

  1990cited by this paper
• Classification of hepatic venous outflow obstruction: ambiguous terminology of the Budd-Chiari syndrome.

  1990cited by this paper
• Etiology of portal vein thrombosis in adults. A prospective evaluation of primary myeloproliferative disorders.

  1988cited by this paper
• Erythropoietic colonies in a serum‐free system: results in primary proliferative polycythaemia and thrombocythaemia

  1987cited by this paper
• A prospective study of the value of bone marrow erythroid progenitor cultures in polycythemia

  1986cited by this paper
• A prospective study of the value of bone marrow erythroid progenitor cultures in polycythemia.

  1986cited by this paper
• Primary myeloproliferative disorder and hepatic vein thrombosis. A prospective study of erythroid colony formation in vitro in 20 patients with Budd-Chiari syndrome.

  1985cited by this paper
• Erythropoietin-dependent primary pure erythrocytosis.

  1979cited by this paper
• THE MANAGEMENT OF POLYCYTHAEMIA VERA *

  1971cited by this paper
• A therapeutic dilemma

  1962cited by this paper

• Genetic Diagnosis and Combinational Treatment With Pharmacomechanical Thrombectomy and Transjugular Intrahepatic Portosystemic Shunt for Non-cirrhotic and Non-malignant Portal Vein Thrombosis

  2025cites this paper
• Navigating the crossroads: exploring the intersection of celiac disease and Budd–Chiari syndrome – insights, challenges, and management strategies

  2025influential citation
• The etiology of chronic splanchnic vein thrombosis in adults: a two-center analysis.

  2025cites this paper
• Splenectomy unveils thrombocytosis in underlying myeloproliferative neoplasms with extrahepatic portal vein obstruction.

  2024cites this paper
• A Case of Budd-Chiari Syndrome Secondary to Tumor Thrombosis

  2024cites this paper
• Hepatic vein thrombosis and PVT: A personal view on the contemporary development of ideas

  2024cites this paper
• JAK2 mutational status and the contribution of TERT and JAK2 polymorphisms to the occurrence of myeloproliferative neoplasms in Eastern Morocco

  2024cites this paper
• A Clinical Case of Timely Diagnosis and Successful Treatment of Budd-Chiari Syndrome With Fulminant Cytolysis in the Setting of a First-time Diagnosed Myeloproliferative Disease.

  2024cites this paper
• The Role of Direct Oral Anticoagulants in Managing Myeloproliferative Neoplasms Patients

  2024cites this paper
• New genetic drivers in hemorrhagic hereditary telangiectasia.

  2023cites this paper
• Stenting of inferior right hepatic vein in a patient with Budd-Chiari syndrome: a case report.

  2023cites this paper
• JAK2 V617F Mutation in Patients with Thrombosis

  2023cites this paper
• Assessment of relation between JAK2 gene and thrombosis in myeloproliferative neoplasms

  2022cites this paper
• JAK2 in Myeloproliferative Neoplasms: Still a Protagonist

  2022cites this paper
• Cavernomul portal la copil – complicaţii şi evoluţie

  2022cites this paper
• Budd-Chiari Syndrom, Review und Illustration der Bildgebung

  2021cites this paper
• JAK2V617F positive polycythemia vera with paroxysmal nocturnal hemoglobinuria and visceral thromboses: a case report and review of the literature

  2021cites this paper
• Budd-Chiari syndrome in small hepatic veins: A diagnostic and therapeutic challenge in a low resource setting

  2021cites this paper
• Alterations in Faecal Metagenomics and Serum Metabolomics Indicate Management Strategies for Patients With Budd-Chiari Syndrome

  2021cites this paper
• JAK2 Gene

  2020cites this paper
• Venous thrombosis of the liver: current and emerging concepts in management.

  2020cites this paper
• ACG Clinical Guideline: Disorders of the Hepatic and Mesenteric Circulation.

  2020cites this paper
• Case Report : A case of PAI-1 4 G / 5 G heterozygosity causing Budd-Chiari Syndrome [ version 2 ; peer review : 2 approved with reservations ]

  2020cites this paper
• JAK2V617F Mutation in Patient with Splanchnic Vein Thrombosis

  2020cites this paper
• Janus Kinase 2 Mutation-Associated Budd-Chiari Syndrome Presenting as a Tumor.

  2020cites this paper
• Review of Budd-Chiari Syndrome

  2020cites this paper
• JAK-2 Positive Polycythemia Vera with Paroxysmal Nocturnal Hemoglobinuria and Splanchic Thromboses: A Case Report and Review of the Literature.

  2020cites this paper
• LAMP: disease classification derived from layered assessment on modules and pathways in the human gene network

  2020cites this paper
• Budd-Chiari Syndrome: An Uncommon Cause of Chronic Liver Disease that Cannot Be Missed.

  2020cites this paper
• History of Budd–Chiari Syndrome

  2019cites this paper
• Portal vein thrombosis post-splenectomy in thalassemia major patients

  2019cites this paper
• Case Report: A case of PAI-1 4G/5G heterozygosity causing Budd-Chiari Syndrome

  2019cites this paper
• Venous Thromboses at Unusual Sites

  2019cites this paper
• Milestones in the discovery of Budd‐Chiari syndrome

  2019cites this paper
• Mutation Status in Myeloid Malignancies Informs Clinical Insight

  2019cites this paper
• Clonal Hematopoiesis with Oncogenic Potential (CHOP): Separation from CHIP and Roads to AML

  2019cites this paper
• The PVSG/WHO versus the Rotterdam European clinical, molecular and pathological diagnostic criteria for the classification of myeloproliferative disorders and myeloproliferative neoplasms (MPD/MPN): From Dameshek to Georgii, Vainchenker and Michiels 1950-2018

  2019cites this paper
• Etiology, presenting features and outcome of children with non-cirrhotic portal vein thrombosis: A multicentre national study.

  2019cites this paper
• Case Report : A case of PAI-1 4 G / 5 G heterozygosity causing Budd-Chiari Syndrome

  2019cites this paper
• Epidemiology of polycythemia vera in a Mexican population

  2019cites this paper
• Venous thrombosis in unusual sites: A practical review for the hematologist

  2018cites this paper
• 11 – Vascular Disorders

  2018cites this paper
• Venous Thrombophilia, Platelet von Willebrand Factor Mediated Arteriolar Microvascular Thrombosis in JAK2V617F Mutated Thrombocythemia and Acquired ADAMTS13 Deficiency as Causes of Intrahepatic Obstructive Microvascular Liver Diseases in Budd-Chiari Syndrome and Splanchnic Vein Thrombosis

  2018cites this paper
• Budd–Chiari syndrome/hepatic venous outflow tract obstruction

  2018cites this paper
• Prevalence of the JAK 2 V 617 F mutation associated with splanchnic vein thrombosis . A 10-year retrospective study

  2018cites this paper
• How We Treat Patients With Polycythemia Vera

  2017cites this paper
• Should We Screen for Janus Kinase 2 V617F Mutation in Cerebral Venous Thrombosis?

  2017cites this paper
• Vascular diseases of the liver. Clinical Guidelines from the Catalan Society of Digestology and the Spanish Association for the Study of the Liver.

  2017cites this paper
• Vascular diseases of the liver. Clinical Guidelines from the Catalan Society of Digestology and the Spanish Association for the Study of the Liver.

  2017cites this paper
• Budd-Chiari Syndrome in a Patient with JAK-2 Mutation without Myeloprolifrative Disorder

  2017influential citation
• MPL and JAK2 exon 12 mutations in patients with the Budd-Chiari syndrome or extrahepatic portal vein obstruction

  2017cites this paper
• Portal vein thrombosis – a primer for the general physician

  2017cites this paper
• Occult myeloproliferative neoplasms: not so occult any more

  2017cites this paper
• Identification of differentially expressed genes in Budd-Chiari syndrome by RNA-sequencing

  2017influential citation
• 12 Molecular Mechanisms in Philadelphia Negative Myeloproliferative Neoplasia

  2017cites this paper
• Genetic Risk Factors of Venous Thromboembolism in the East Algerian Population

  2017cites this paper
• Splanchnic vein thrombosis in myeloproliferative neoplasms: pathophysiology and molecular mechanisms of disease

  2017cites this paper
• Molecular Pathogenesis of Myeloproliferative Neoplasms: Influence of Age and Gender

  2017cites this paper
• Long‐term outcomes following percutaneous hepatic vein recanalization for Budd–Chiari syndrome

  2017cites this paper
• Bleeding, thrombosis, and anticoagulation in myeloproliferative neoplasms (MPN): analysis from the German SAL-MPN-registry

  2016cites this paper
• Pronóstico de los pacientes muy mayores ingresados en una Unidad de Cuidados Intensivos

  2016cites this paper
• Budd-Chiari syndrome: current perspectives and controversies.

  2016cites this paper
• Unexpected insights in the aetiology and management of abdominal vein thrombosis

  2016cites this paper
• Impact of JAK2V617F Mutational Status on Phenotypic Features in Essential Thrombocythemia and Primary Myelofibrosis

  2016cites this paper
• Myeloid Neoplasms with an Erythroid Cell Lineage

  2016cites this paper
• Myeloproliferative Syndromes and Thrombocythemia

  2016cites this paper
• Diagnosis, etiology and management of the Budd-Chiari Syndrome: a bloodcoagulation and hepatological study on the course of the disease treated with TIPS.

  2016cites this paper
• Association of factor V Leiden, Janus kinase 2, prothrombin, and MTHFR mutations with primary Budd–Chiari syndrome in Egyptian patients

  2016cites this paper
• Inpatient Medicine

  2015cites this paper
• PORTAL VEIN THROMBOSIS: ETIOLOGY, DIAGNOSIS AND MANAGEMENT A REVIEW

  2015cites this paper
• Diagnostic value of the JAK2 V617F mutation for latent chronic myeloproliferative disorders in patients with Budd-Chiari syndrome and/or portal vein thrombosis.

  2015cites this paper
• Three Phenotypes of JAKV617F Mutated Essential Thrombocythemia and Early Thrombocythemic Stage of Polycythemia Vera in 10 Patients: Important to Differentiate because Natural History Differ

  2015influential citation
• Diagnostic value of the JAK 2 V 617 F mutation for latent chronic myeloproliferative disorders in patients with budd-chiari syndrome and / or portal vein thrombosis

  2015cites this paper
• Budd–Chiari syndrome complicating essential thrombocythemia in an adolescent: favorable outcome of TIPS procedure

  2015cites this paper
• Somatic calreticulin mutations in patients with Budd-Chiari syndrome and portal vein thrombosis

  2015cites this paper
• Somatic calreticulin mutations in patients with Budd-Chiari syndrome and portal vein thrombosis

  2015cites this paper
• Thrombotic Venous Diseases of the Liver

  2015cites this paper
• Portal vein thrombosis.

  2015cites this paper
• Acute Portal Vein Thrombosis: Aetiopathogenesis, Diagnosis and Management

  2015cites this paper
• Budd-Chiari syndrome and liver transplantation.

  2015cites this paper
• Identifying Sub-Network Functional Modules in Protein Undirected Networks

  2014cites this paper
• FunMod: A Cytoscape Plugin for Identifying Functional Modules in Undirected Protein–Protein Networks

  2014cites this paper
• Good clinical outcomes following transjugular intrahepatic portosystemic stent‐shunts in Budd–Chiari syndrome

  2014cites this paper
• Myeloproliferative neoplasms and recurrent thrombotic events in patients undergoing liver transplantation for Budd-Chiari syndrome: a single-center experience.

  2014cites this paper
• Treatment of gastric varices with partial splenic embolization in a patient with portal vein thrombosis and a myeloproliferative disorder.

  2014cites this paper
• Cooperation between pathologists and clinicians allows a better diagnosis of Philadelphia chromosome-negative myeloproliferative neoplasms

  2014cites this paper
• reactivity in a knock-in mouse model of essential thrombocythemia JAK2V617F leads to intrinsic changes in platelet formation and

  2014cites this paper
• An overview of current treatment methods for Budd–Chiari syndrome

  2014cites this paper
• Myeloproliferative neoplasia : more insight in the pathogenesis

  2014influential citation
• JAK2 V617F mutation and 46/1 haplotype in Chinese Budd‐Chiari syndrome patients

  2014cites this paper
• PLATELETS AND THROMBOPOIESIS JAK2V617F leads to intrinsic changes in platelet formation and reactivity in a knock-in mouse model of essential thrombocythemia

  2013cites this paper
• Long-term Follow-up Study in Budd-Chiari Syndrome: Single-center Experience in 22 Years

  2013cites this paper
• PLATELETS AND THROMBOPOIESIS JAK2V617F leads to intrinsic changes in platelet formation and reactivity in a knock-in mouse model of essential thrombocythemia

  2013cites this paper
• PLATELETS AND THROMBOPOIESIS JAK2V617F leads to intrinsic changes in platelet formation and reactivity in a knock-in mouse model of essential thrombocythemia

  2013cites this paper
• expert panel primary myelofibrosis: recommendations from an ad hoc international diagnostic criteria for polycythemia vera, essential thrombocythemia, and Proposals and rationale for revision of the World Health Organization

  2013cites this paper
• PLATELETS AND THROMBOPOIESIS JAK2V617F leads to intrinsic changes in platelet formation and reactivity in a knock-in mouse model of essential thrombocythemia

  2013cites this paper
• PLATELETS AND THROMBOPOIESIS JAK2V617F leads to intrinsic changes in platelet formation and reactivity in a knock-in mouse model of essential thrombocythemia

  2013cites this paper
• Hepatic Manifestations in Hematological Disorders

  2013cites this paper
• PLATELETS AND THROMBOPOIESIS JAK2V617F leads to intrinsic changes in platelet formation and reactivity in a knock-in mouse model of essential thrombocythemia

  2013cites this paper
• PLATELETS AND THROMBOPOIESIS JAK2V617F leads to intrinsic changes in platelet formation and reactivity in a knock-in mouse model of essential thrombocythemia

  2013cites this paper